MindMaze Therapeutics Holding S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RLFTF research report →
About the company
MindMaze Therapeutics Holding SA engages in the development of AI-powered neurotherapeutics and pharmacological treatments for brain disorders. It focuses on addressing neurological and neuropsychiatric conditions through advanced research, clinical development, and technology-driven solutions. The company is headquartered in Geneva, Switzerland.
- CEO
- Zach Henderson
- IPO
- 2021
- Employees
- 30
- HQ
- Geneva, GE, CH
Price Chart
- Revenue
- $642.31K · -92.37%
- Net Income
- $-9,910,748 · 42.11%
- EPS
- $-0.48 · 64.96%
- Op Income
- $-10,520,040
- FCF YoY
- -325.53%
- 52W High
- $4.88
- 52W Low
- $0.25
- 50D MA
- $0.42
- 200D MA
- $1.83
- Beta
- 1.25
- Avg Volume
- 4.01K
Get TickerSpark's AI analysis on RLFTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RLFTF coverage
Recent articles, reports, and earnings notes.
No research on RLFTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RLFTF report →Similar companies
Peers in the same neighborhood.